Country

Clinical trials in Czechia

Active obesity and GLP-1 studies with at least one location in Czechia.

41active studies

20recruiting now

35countries represented

243largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Obesity With Diabetes, Overweight With DiabetesCondition

Ribupatide, PlaceboTreatment

Argentina, Australia167 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284901See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Czechia, Germany136 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743450See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowNot applicable

Safety and Effectiveness of Orbera365™ Intragastric Balloon System

ObesityCondition

Intragastric BalloonTreatment

Czechia, Spain4 locations

Boston Scientific CorporationSponsor

Updated 2026-08-13 · NCT07062094See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowNot applicable

Bone Marrow Adipose Tissue in Relation to Bone and Energy Metabolism in Obesity and Type 2 Diabetes Mellitus

ObesityCondition

Caloric RestrictionTreatment

Czechia3 locations

General University Hospital, PragueSponsor

Updated 2026-07-28 · NCT07731438See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Chronic Kidney DiseaseCondition

NNC0519-0130, PlaceboTreatment

Argentina, Australia147 locations

Novo Nordisk A/SSponsor

Updated 2026-03-11 · NCT06717698See eligibility →

Recruiting nowNot applicable

Small Bowel Diversion

Obesity, Type2 DiabetesCondition

jejuno-ileal diversion, jejuno-colic diversionTreatment

Czechia2 locations

University of OstravaSponsor

Updated 2025-08-19 · NCT06374368See eligibility →

Recruiting nowNot applicable

National Childhood Obesity Prevention Programme BE FIT 24

Childhood ObesityCondition

Motivation Engagement for Movement and Interactive Nutrition DevelopmentTreatment

Czechia1 locations

Institute of Health Information and Statistics of the Czech RepublicSponsor

Updated 2025-07-09 · NCT07057453See eligibility →

Recruiting nowNot applicable

Non-invasive Brain Stimulation to Prepare the Patient for Bariatric Surgery (REBAS)

ObesityCondition

home-based tDCS stimulation, home-based tDCS stimulation - shamTreatment

Czechia2 locations

Masaryk UniversitySponsor

Updated 2025-03-13 · NCT06874309See eligibility →

Recruiting nowNot applicable

ENDOPLY System in Humans: a Pilot Study

ObesityCondition

ENDOPLY SystemTreatment

Czechia1 locations

ENDOPLYSponsor

Updated 2025-02-25 · NCT06292728See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

Osteoarthritis in the Knee, ObesityCondition

KBP-336, PlaceboTreatment

Czechia, Denmark20 locations

KeyBioscience AGSponsor

Updated 2025-02-19 · NCT06833749See eligibility →

Recruiting nowNot applicable

AI-POD Clinical Validation Study for Obese Patients

Acute Cardiovascular DiseaseCondition

Non InterventionalTreatment

Austria, Belgium6 locations

University Hospital, BonnSponsor

Updated 2024-09-19 · NCT06595134See eligibility →

Recruiting nowNot applicable

Global Research Initiative for Patients Screening on MASH

MASH, MASLDCondition

Intervention not listedTreatment

Belgium, Czechia13 locations

Julius ClinicalSponsor

Updated 2024-08-01 · NCT05651724See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Invitation onlyNot applicable

Pilot Validation of the STELA Preventive Medicine Platform to Reduce Modifiable Health Risk Factors in Adults (CPM-STELA)

Cardiovascular Risk Factors, Insulin ResistanceCondition

STELA Digital Preventive Medicine Platform, Comprehensive Preventive Health AssessmentTreatment

Czechia1 locations

Nemocnice AGEL Trinec-Podlesi a.s.Sponsor

Updated 2026-04-27 · NCT07551960See eligibility →

Invitation onlyNot applicable

Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.

Obesity & OverweightCondition

Urolithin A 500mg, PlaceboTreatment

Czechia1 locations

Charles University, Czech RepublicSponsor

Updated 2026-02-19 · NCT07377136See eligibility →

Active, not recruitingPhase 3

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Argentina, Bulgaria188 locations

PfizerSponsor

Updated 2026-09-08 · NCT07400653See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and OverweightCondition

MET097, PlaceboTreatment

Bulgaria, Canada169 locations

PfizerSponsor

Updated 2026-09-04 · NCT07311850See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Overweight, ObesityCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

Argentina, Canada67 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07220759See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Semaglutide, Placebo (semaglutide)Treatment

Brazil, Bulgaria229 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT03811561See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingNot applicable

Evaluation of Molecular Hydrogen Supplementation to Enhance the Efficacy of Weight Loss Retreat in Overweight and Obese Adolescents

Body Composition, FitnessCondition

Hydrogen-rich water, PlaceboTreatment

Czechia1 locations

Palacky UniversitySponsor

Updated 2026-06-02 · NCT06961110See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingNot applicable

Development of Human Motor Skills and the Promotion of Motivation for Physical Activity

Physical Inactivity, Obesity & OverweightCondition

E-MOVE - Emotional Movement Program for Physical EducationTreatment

Czechia9 locations

Charles University, Czech RepublicSponsor

Updated 2026-03-20 · NCT07485270See eligibility →

Active, not recruitingPhase 3

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

Type 1 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Brazil79 locations

Eli Lilly and CompanySponsor

Updated 2026-02-17 · NCT06962280See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Bulgaria187 locations

AmgenSponsor

Updated 2025-12-31 · NCT06858878See eligibility →

Active, not recruitingPhase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

ObesityCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia243 locations

AmgenSponsor

Updated 2025-10-20 · NCT06858839See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

OSA, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, Brazil66 locations

Eli Lilly and CompanySponsor

Updated 2025-09-29 · NCT06649045See eligibility →

Active, not recruitingNot applicable

Multinational Point Prevalence Study on the Management of Diabesity in Hospitals

Diabetes Mellitus, ObesityCondition

Routine care for people with diabetes, with or without obesity, in the hospital settingTreatment

Austria, Czechia8 locations

Medical University of ViennaSponsor

Updated 2025-05-08 · NCT06680674See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.